---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059124"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:04:16.927049+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics Q1 2024 net loss $28.1M; expands autoimmune plans

## Summary
- Net loss of $28.1M for Q1 2024 vs $31.3M in Q1 2023; R&D expenses $23.4M, down from $24.9M.
- Cash, cash equivalents and marketable securities $249.9M as of March 31, 2024; cash runway into 2026.
- Closed $60M private placement led by Bain Capital Life Sciences in April 2024.
- Plans additional regulatory filings for CNTY-101 in autoimmune diseases beyond SLE in H2 2024.
- FY2024 GAAP operating expense guidance raised to $150-160M (prior $135-145M) due to Clade acquisition and expansion.

## SEC filing metadata
- accession: 0001104659-24-059124
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465924059124/0001104659-24-059124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465924059124/tm2413916d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059124
- JSON: https://secwatch.observer/filing/0001104659-24-059124.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059124.txt

## Key facts
- Earnings Releases
  Century Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune diseases, today reported financial results and business highlights for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465924059124/0001104659-24-059124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.